The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Eligibility rate
Timeframe: assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Consent rate
Timeframe: assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Trial entry rate
Timeframe: assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Completion rate
Timeframe: assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Missing data rate
Timeframe: assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Patient engagement
Timeframe: assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Drop out rate
Timeframe: assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Adverse events
Timeframe: assessed from study start in May 2021 until study completition in May 2022, up to 1 year
Acceptability of Module I
Timeframe: after completion of Module I in week 1
Acceptability of Module II
Timeframe: after completion of Module II in week 3
Acceptability of Module III
Timeframe: after completion of Module III in week 5
Semi-structured interviews
Timeframe: after completing Module III in week 5